Teva's Experimental Celiac Drug Shows Promise in Protecting Gut
Translated & summarized from Vesty by baba
Teva Pharmaceuticals has reported promising interim results for its experimental antibody, TEV-408, in a Phase 2a trial for celiac disease. The drug demonstrated a protective effect on the gut against gluten and reduced inflammation, potentially offering the first pharmaceutical treatment for the condition.
The story in 6 lines · by baba
- Teva's experimental drug TEV-408 shows promise in protecting the gut from gluten damage.
- A clinical trial indicated reduced inflammation and fewer symptoms in celiac patients receiving the drug.
- TEV-408 targets the IL-15 protein, a key factor in the autoimmune response of celiac disease.
- The drug is also being tested for vitiligo, leveraging a shared immune mechanism.
- If approved, TEV-408 could be the first pharmaceutical treatment for celiac disease.
- The FDA has granted Fast Track designation for the drug's development.
Teva Pharmaceuticals announced positive interim results from a Phase 2a clinical trial for its experimental drug TEV-408, an antibody designed to treat celiac disease. The study, involving 50 adult celiac patients, indicated that a single dose of TEV-408 could protect the small intestine from gluten-induced damage and reduce inflammation. Participants received either the drug or a placebo, followed by a six-week period of daily gluten exposure. Researchers measured the height of intestinal villi relative to the depth of crypts, a key indicator of gut damage. The results showed a significantly smaller reduction in this ratio in the drug group (0.43 points) compared to the placebo group (0.88 points), a statistically significant and clinically meaningful difference. Inflammation markers also showed a more substantial increase in the placebo group than in the TEV-408 group. Patients in the drug group also reported fewer digestive symptoms.
TEV-408 works by blocking the protein IL-15, which is believed to trigger the immune response that damages the gut lining in celiac patients after gluten exposure. This mechanism is also being explored for treating vitiligo, another autoimmune condition. Teva's research and development for this antibody have been supported by significant funding, with potential sales estimated in the billions of dollars. The drug is being developed in Teva's laboratories in Netanya, Israel, with project management also based there.
Currently, the only treatment for celiac disease is a strict, lifelong gluten-free diet, which does not always prevent symptoms or gut damage for all patients. Teva's drug, if approved, could represent the first pharmaceutical treatment for the condition. The U.S. Food and Drug Administration (FDA) granted Fast Track designation for the drug's development in May 2025. Teva plans to present further data at an upcoming scientific conference, emphasizing that these are interim results and further trials are necessary to confirm efficacy and safety. The drug was well-tolerated with no observed side effects.
Mentioned
